missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Human Progesterone Receptor, Ligand Binding Domain, GST Tag Recombinant Protein

Recombinant Protein

Marke:  Invitrogen™ A15672

Artikelnummer. 15430420

  • 1150.00 EUR / 600µg

Please to purchase this item. Need a web account? Register with us today!

Entdecken Sie weitere Sonderangebote
Dieser Artikel kann nicht zurückgegeben werden. Rückgaberichtlinie anzeigen

Beschreibung

Beschreibung

Progesterone receptor ligand binding domain (PR-LBD) is a 59.83 kDa recombinant human protein (amino acids 675-933) expressed as a glutathione-S-transferase (GST) fusion protein in baculovirus-infected insect cells. PR is expressed and purified in the absence of exogenous ligands, making it ideal for ligand binding and coregulator displacement studies. PR-LBD human recombinant protein is: , Flexible—use in your in-house assay or as part of our PolarScreen™ Competitor assays for a complete assay solution, Ready to use—active and tagged (with GST), Convenient—available in bulk sizes Contact us for bulk quantities or for assistance with other nuclear receptor assay needs, from assay development to library screening and beyond. Used in:PolarScreen™ Progesterone Receptor Competitor Assay, RedPolarScreen™ Progesterone Receptor Competitor Assay, Green, Protein Form: Ligand Binding Domain, Recombinant

The progesterone receptor (PR) is a member of the steroid family of nuclear receptors. The PR mediates the physiological effects of progesterone, which plays a central role in reproductive events associated with the establishment and maintenance of pregnancy. PR is found as a 94 kDa protein (Form A) or a 120 kDa protein (Form B) due to the use of alternative translation initiation sites. PR-B is the transcriptionally active form and is responsible for activating genes for the maintenance of the endometrium, maintenance of pregnancy, and inhibition of ovulation. PR-A is identical to PR-B except for a 165 amino acid deletion at the N-terminus. This deletion exposes a 140 amino acid inhibitory domain (ID) that acts as a repressor of steroid hormone transcriptional activity. In its inactive state, PgR forms a multiprotein complex which includes heat shock proteins and immunophins. Upon binding of progesterone hormone to its receptor, there is a conformational change that allows dimerization and binding of the receptor to progesterone response elements (PRE) sequences, resulting in activated transcription. A Null mutation in the PGR gene leads to pleiotrophic reproductive abnormalities.
TRUSTED_SUSTAINABILITY
Spezifikation
Show More
Produktvorschläge

Produktvorschläge

Videos
Sicherheitsdatenblatt (SDS)
Dokumentation

Dokumentation

Zertifikate

Certificates

A lot number is required to show results for certificates. To find your lot number on previous orders use our order status area.

5 results found
Lot Number Certificate Type Date Catalog Number
Lot Number2708601B Certificate TypeCertificate of Analysis Date03/02/2024 Catalog NumberA15672
Lot Number2708601A Certificate TypeCertificate of Analysis Date15/07/2023 Catalog NumberA15672
Lot Number2470645F Certificate TypeCertificate of Analysis Date09/05/2023 Catalog NumberA15672
Lot Number2470645E Certificate TypeCertificate of Analysis Date24/03/2023 Catalog NumberA15672
Lot Number2470645C Certificate TypeCertificate of Analysis Date06/08/2022 Catalog NumberA15672
Sonderangebote

Sonderangebote

Berichtigung von Produktinhalten

Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.

Name des Produkts
Invitrogen™ Human Progesterone Receptor, Ligand Binding Domain, GST Tag Recombinant Protein > 0.6 mg; Unlabeled

Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.

Vielen Dank, dass Sie uns helfen, unsere Website zu verbessern. Ihr Feedback wurde übermittelt